Norito Katoh

Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*

Andreas Wollenberg, Andrew Blauvelt, Emma Guttman‐Yassky et al. · British Journal of Dermatology · 2020 · 595 citations · Full text

Medicine, Dermatology, Pharmacotherapy +16

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

Emma Guttman‐Yassky, Henrique D. Teixeira, Eric L. Simpson et al. · The Lancet · 2021 · 543 citations

Life Sciences, Dermatology, Pharmacotherapy +13

Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial

Kristian Reich, Jacob P. Thyssen, Andrew Blauvelt et al. · The Lancet · 2022 · 237 citations

Life Sciences, Dermatology, Immunology +12

Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Eric L. Simpson, Kim Papp, Andrew Blauvelt et al. · JAMA Dermatology · 2022 · 204 citations · Full text

Medicine, Dermatology, Pharmacotherapy +12

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

Hidehisa Saeki, Takeshi Nakahara, Akio Tanaka et al. · The Journal of Dermatology · 2016 · 172 citations

Medicine, Dermatology, Immunology +17